Core Viewpoint - Company Kintor Pharmaceutical (科济药业-B) is set to present clinical data for its CAR-T cell therapy candidate CT0596 at the 67th American Society of Hematology Annual Meeting, with further details to be released on November 3, 2025 [1] Group 1: Product Information - CT0596 is a universal CAR-T cell therapy targeting BCMA, developed on the company's proprietary THANK-u Plus™ platform [1] - The therapy is currently undergoing investigator-initiated clinical trials for relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) [1] - Initial results indicate promising safety and efficacy signals, with CAR-T cell expansion observed across all predefined dose groups [1] Group 2: Future Plans - In addition to R/R MM, the company plans to explore CT0596 in other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells [1] - The company anticipates submitting an IND application for CT0596 in the second half of 2025 [1]
科济药业-B(02171)：于2025年ASH年会上呈列的CT0596的研究成果更新